Amarin Corp Plc\uk

  • Moat Score
  • Market Cap $207.69M
  • PE -5
  • Debt $0.00
  • Cash $156.94M
  • EV $50.75M
  • FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$39.35M
EBIT-$29.74M
ROE-7%
ROA-4%
Equity$531.38M
Growth Stability1
PE-5.28
PB0.39
P/S0.86
Price/Cash0.76
Debt/Equity0
Net Margins-20%
Gross Margins56%
Op. Margins-12%
Sales Growth YoY-36%
Sales Growth QoQ-37%
Sales CAGR17%
Equity CAGR19%
Earnings Growth YoY30%
Earnings Growth QoQ-2K%
Sales CAGR 5Y-17%
Equity CAGR 5Y-3%
Earnings CAGR 3Y-26%
Sales CAGR 3Y-26%
Equity CAGR 3Y-7%
Market Cap$207.69M
Revenue$241.02M
Assets$750.62M
Total Debt$0.00
Cash$156.94M
Shares Outstanding410.79M
EV50.75M
Moat Score5%
Working Capital448.66M
Current Ratio3.23
Gross Profit$136.07M
Shares Growth 3y2%
Equity Growth QoQ-4%
Equity Growth YoY-4%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its lead product includes Vascepa.

SEC Filings

Direct access to Amarin Corp Plc\uk (AMRN) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Amarin Corp Plc\uk compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Amarin Corp Plc\uk compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Amarin Corp Plc\uk Discounted Cash Flow

Fully customizable DCF calculator online for Amarin Corp Plc\uk.

0
012345678910TV
fcf$0$0$0$0$0$0$0$0$0$0$0$0
DCF$0$0$0$0$0$0$0$0$0$0$0
Value$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins-104%-182%-66%-37%-51%-5%-3%1%-29%-19%-20%
ROA--57%-39%-28%-28%-3%-2%1%-12%-6%-4%
ROE-115%953%104%-76%-4%-3%1%-18%-11%-7%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF---1.41-3.49-1.2-8.43-0----
Debt over Equity-1.19-0.82-11.16-1.760.750.1600000
Growth Stability----------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth-51%59%39%27%87%43%-5%-37%-17%-17%
Earnings YoY growth-164%-42%-21%72%-81%-21%-143%-1K%-44%-
Equity YoY growth-46%-93%619%-334%299%3%6%-11%-7%-3%
FCF YoY growth---15%-54%188%-88%86%----